Dendritic Cells RNA Silencing Guide

Master RNA Silencing in Dendritic Cells

Engineer DC vaccines and tolerogenic DCs without triggering maturation

Typically 70-90%

Knockdown Efficiency

Typically >95%

Cell Viability

Yes

Immature Phenotype Preserved

Why Dendritic Cells Are Critical for Immunotherapy and Vaccine Research

Dendritic cells (DCs) are professional antigen-presenting cells that serve as the critical bridge between innate and adaptive immunity . DCs capture antigens at tissue sites, migrate to lymph nodes , and present processed antigens via MHC-I (cross-presentation to CD8+ T cells) and MHC-II (to CD4+ T cells) . This unique cross-presentation capacity allows DCs to initiate cytotoxic T lymphocyte (CTL) responses against tumors and viruses , making them essential for cancer immunotherapy and vaccine development.

DC subsets have specialized functions: cDC1s (BATF3-dependent, CD141+ in humans, CD8α+ in mice) excel at cross-presentation and IL-12 production for Th1 responses ; cDC2s (IRF4-dependent, CD1c+ in humans, CD11b+ in mice) prime CD4+ T cells and drive Th17 responses ; plasmacytoid DCs (pDCs) produce exceptionally high amounts of type I interferon (IFN-α/β, 100-1000× more than most other cell types depending on stimulation conditions) in response to viral nucleic acids via TLR7/9, critical for antiviral immunity ; monocyte-derived DCs (mo-DCs) can be generated in vitro from CD14+ monocytes with GM-CSF and IL-4, serving as the workhorse for DC vaccine manufacturing .

The fundamental challenge: transfection triggers DC maturation, destroying immature phenotype. Dendritic cell biology is exquisitely sensitive to activation signals . Lipofection efficiency in primary human mo-DCs is <10% with 50-70% cell death , but the more critical problem is that cationic lipids trigger DC maturation within 2-4 hours, upregulating CD80, CD86, CD83, MHC-II, and inducing IL-12 production . This maturation is mediated by TLR activation (lipoplexes mimic pathogen-associated patterns) and creates catastrophic artifacts: studies examining immature DC biology, tolerogenic DC generation, or staged maturation become impossible because transfection itself forces maturation.

Electroporation can cause significant cell death (often 40-70% with non-optimized protocols, though clinical-grade optimized protocols achieve better viability), may disrupt dendritic morphology (cells can become rounded), and sometimes induces maturation; outcomes depend on DC state and protocol . Even viral transduction activates innate sensing pathways (cGAS-STING for DNA sensing, RIG-I/MDA5 for RNA sensing), inducing type I interferon and maturation .

AUMsilence self-delivering ASO technology enables authentic DC research without maturation artifacts. AUMsilence sdASOs enter cells via receptor-mediated endocytosis of their phosphorothioate-modified backbones , followed by intracellular trafficking; a small fraction escapes endosomes to reach the cytosol and nucleus where target engagement occurs via RNase H1 . This mechanism typically achieves 70-90% gene knockdown in primary mo-DCs and DC lines while preserving immature phenotype: no upregulation of CD80, CD86, CD83, or cytokine secretion . This enables: (1) DC vaccine optimization for cancer immunotherapy (knockdown immunosuppressive molecules IDO1, PD-L1, BTLA to enhance T cell activation) , (2) tolerogenic DC generation for autoimmune diseases and transplant tolerance (knockdown CD40, CD80, CD86, IL-12B to prevent T cell activation and induce regulatory T cells) , (3) cross-presentation pathway dissection (TAP1/TAP2, SEC22B, ERAP1 to understand how DCs present extracellular antigens on MHC-I) , (4) plasmacytoid DC interferon production studies (IRF7, TLR7/9, MYD88 in antiviral responses and lupus pathology) , (5) tumor DC dysfunction modeling (STAT3, VEGFR to understand how tumors disable DCs) .

Applications span cancer immunotherapy (DC vaccines, checkpoint modulation), autoimmune disease treatment (tolerogenic DCs for Treg induction), infectious disease vaccines, transplant tolerance, and basic immunology (antigen presentation, DC migration, T cell priming mechanisms).

DCs bridge innate and adaptive immunity through antigen presentation and T cell priming

DC subsets: cDC1 (cross-presentation, IL-12) , cDC2 (Th17) , pDC (type I IFN) , mo-DC (in vitro)

Lipofection <10% efficiency in mo-DCs and triggers maturation artifacts (CD80↑, CD86↑, IL-12)

Electroporation causes variable cell death (40-70%) and may induce maturation depending on protocol

Critical problem: Transfection activates TLRs, forcing DC maturation and destroying immature phenotype

AUMsilence typically achieves 70-90% knockdown without maturation; preserves CD80low, CD86low, MHC-IIlow

Enables DC vaccine engineering [25-28], tolerogenic DC generation , and cross-presentation studies

Critical Challenges in Dendritic Cell Transfection

Transfection-Induced DC Maturation Destroys Immature Phenotype

Dendritic cells exist in two functional states: immature (antigen capture, tissue-resident) and mature (T cell activation, lymph node-resident) . Immature DCs express low CD80, CD86, CD83, MHC-II and high endocytic activity . Maturation upregulates costimulatory molecules, MHC-II, and cytokine production (IL-12, IL-6, TNF-α) . The critical problem: cationic lipids and electroporation trigger DC maturation via TLR2/TLR4 activation , causing immature DCs to mature within 2-4 hours . This creates experimental artifacts; studies requiring immature DCs (tolerogenic DC generation, antigen uptake kinetics, migration studies) become impossible because transfection itself forces maturation . This confounds many critical DC biology studies, particularly those requiring immature DC phenotypes for mechanistic investigation.

High Impact

Extremely Low Lipofection Efficiency with High Toxicity

Primary monocyte-derived DCs (mo-DCs) achieve <10% lipofection efficiency with 50-70% cell death within 24 hours . DCs are professional phagocytes but traffic lipoplexes to acidic lysosomes (pH 4.5) with high nuclease activity, degrading payloads before they reach cytosol . The 5-10% of cells that do take up reagent often show altered morphology (loss of dendrites), reduced viability, and aberrant maturation . Even established DC cell lines (human and mouse) show only 15-25% lipofection efficiency . This low efficiency makes population-level gene silencing studies unreliable .

High Impact

Electroporation-Induced Cell Death and Potential Loss of Dendritic Morphology

Dendritic cells are sensitive to physical membrane disruption . Electroporation typically causes 40-70% cell death, and surviving DCs may lose characteristic dendritic morphology: cells can become round and detach . The dendritic projections that define DCs and enable T cell scanning can be disrupted by electroporation-induced membrane damage and cytoskeletal changes . Electroporated DCs may show reduced migration to lymph nodes (impaired CCR7 responsiveness) , diminished T cell priming capacity, and altered cytokine secretion . The severity varies with protocol parameters and DC maturation state . Note that many clinical DC vaccines successfully use optimized mRNA electroporation protocols, though careful optimization is critical .

High Impact

Viral Transduction Activates Innate Sensing and Type I Interferon

DCs are sentinels of the immune system, equipped with pattern recognition receptors (TLRs, RIG-I, cGAS-STING) to detect pathogens . Viral vectors (lentivirus, AAV, adenovirus) trigger these pathways: cytosolic viral nucleic acids activate cGAS-STING (DNA sensing) or RIG-I (RNA sensing), inducing massive type I interferon (IFN-α/β) production and interferon-stimulated gene (ISG) expression within 4-6 hours . This interferon response drives DC maturation and creates a globally altered transcriptional state . Plasmacytoid DCs are especially sensitive; viral transduction triggers their primary function (interferon production), making any functional study unreliable .

High Impact

Subset-Specific Transfection Challenges

Different DC subsets have varying transfection sensitivities: Plasmacytoid DCs (pDCs) are nearly impossible to transfect (<5% efficiency) and die rapidly with any transfection method due to extreme fragility and interferon-mediated apoptosis . Primary tissue-isolated cDC1s and cDC2s are rare (0.01-0.1% of PBMCs), making optimization difficult, and show <5% lipofection efficiency . Mo-DCs (most commonly used) are more robust but still show <10% efficiency . This subset-specific variability makes it difficult to establish standardized protocols, and often forces researchers to use mo-DCs as surrogates for rare primary DC subsets .

Medium Impact

Maturation State-Dependent Transfection Efficiency

Transfection efficiency varies with maturation state: Immature DCs (the most relevant for many studies) show 5-10% lipofection efficiency . Mature DCs (LPS-treated) show slightly higher efficiency (10-20%) but are already activated, confounding studies . This creates a paradox: the DC state most relevant for tolerogenic DC generation and antigen capture studies (immature) is the most resistant to transfection, while the state that transfects better (mature) is already in the activated state that many experiments aim to avoid .

Medium Impact

Method Comparison

Method	Efficiency	Viability	Pros	Cons
Lipofection (Cationic Lipid Reagents)	5-10%	30-50%	Commercially available, simple protocol	Extremely low efficiency, triggers TLR-mediated DC maturation (CD80↑, CD86↑, IL-12), high cell death, destroys immature phenotype
Electroporation (Nucleofection)	20-40%	20-40%	Higher efficiency than lipofection in some lines, used successfully in some clinical DC vaccines	Causes variable cell death (40-70%), can disrupt dendritic morphology, may induce maturation, protocol-dependent outcomes, expensive equipment required
Viral Vectors (Lentivirus, AAV)	30-60%	50-70%	Moderate efficiency, stable transduction	Activates innate sensing (cGAS-STING, RIG-I), induces massive type I IFN and maturation, 2-4 week production, expensive
AUMsilence sdASO	Typically 70-90% (in DCs; target-dependent and requires empirical validation for each application)	Typically >95% (in DCs; target-dependent and requires empirical validation for each application)	Minimal maturation artifacts, preserves immature phenotype (CD80low, CD86low), sdASO designs minimize innate immune activation through sequence filtering to avoid CpG/TLR stimulatory motifs, maintains dendritic morphology, works in immature and mature DCs, preserves migration and T cell priming	Transient knockdown (ideal for functional studies)

AUMsilence sdASO

The Ideal Solution for Dendritic Cell Gene Silencing

Why This Product?

AUMsilence self-delivering ASOs are uniquely suited for dendritic cell research because they preserve immature DC phenotype: the most critical requirement for DC biology studies. Conventional transfection triggers DC maturation via TLR activation, destroying the immature state required for tolerogenic DC generation, antigen uptake studies, and staged maturation experiments. AUMsilence sdASOs enter cells via receptor-mediated endocytosis without requiring transfection reagents, electroporation, or viral vectors. They typically achieve 70-90% gene knockdown through RNase H1-mediated target degradation, with minimal TLR activation, cytokine induction, or maturation marker upregulation (CD80, CD86, CD83). This enables authentic DC vaccine engineering, cross-presentation pathway dissection, and pDC interferon studies that are difficult or impossible with conventional transfection methods.

Key Benefits

Enables Tolerogenic DC Generation

Knock down CD40, CD80, CD86, IL-12B to generate maximally tolerogenic DCs for autoimmune disease and transplant applications. AUMsilence does not induce maturation; tolerogenic DCs remain immature throughout.

DC Vaccine Engineering for Cancer Immunotherapy

Knock down immunosuppressive molecules (IDO1, PD-L1, BTLA) or enhance IL-12 (SOCS1 knockdown) to generate DCs that robustly activate tumor-specific T cells. Published strategies enabled by AUMsilence.

Cross-Presentation Pathway Dissection

Systematically knock down TAP1, TAP2, ERAP1, SEC22B to define molecular requirements for cross-presenting extracellular antigens on MHC-I to CD8+ T cells. Critical for understanding anti-tumor and antiviral immunity.

Rapid Optimization Timeline

No viral vector cloning, no electroporation optimization. Differentiate monocytes to DCs (6 days), add AUMsilence (3 days), validate knockdown and function. Test gene function in 9-10 days total.

Multi-Gene Knockdown for Synergistic Engineering

Combine IDO1 + PD-L1 knockdown for dual checkpoint targeting. Or CD40 + CD80 + IL-12B for maximally tolerogenic DCs. 5 μM per ASO, 15 μM total. Enables testing combinatorial DC engineering strategies.

Ideal For

Primary monocyte-derived dendritic cells (mo-DCs)
Plasmacytoid dendritic cells (pDCs): human blood-derived
Primary tissue-isolated cDC1 and cDC2 subsets
DC vaccine engineering for cancer immunotherapy
Tolerogenic DC generation for autoimmune diseases and transplantation
Cross-presentation and MHC-I antigen processing studies
pDC interferon biology (antiviral immunity, lupus pathology)
DC maturation pathway dissection
DC-T cell co-culture and priming assays
DC migration and CCR7 studies
Human and mouse DC cell lines
Tumor DC dysfunction modeling (STAT3, VEGFR)
Vaccine adjuvant mechanism studies

Learn More About AUMsilence sdASO

Alternative Products

AUMsaver toASO

When to use: For robust DC cell lines (human and mouse) that are easily transfected, where the self-delivering capability is not required. Cost-effective option for high-throughput screening before validation in primary DCs with AUMsilence.

Learn More →

Custom ASO Design Service

When to use: For novel DC targets or multi-gene DC engineering panels. AUM scientists design and validate 3-5 ASO candidates per target, optimized for human or mouse DC sequences.

Learn More →

AUMsilence Protocols for Dendritic Cells

Optimized protocols for monocyte-derived DCs, primary tissue DCs, plasmacytoid DCs, and DC lines. No transfection reagents required; preserves immature phenotype.

Quick Start Protocol (All DC Types)

Generate mo-DCs from CD14+ monocytes (GM-CSF + IL-4, 6 days) or culture DC lines
Add AUMsilence sdASO directly to culture medium at 10 μM (no transfection reagent)
Incubate 48-72 hours at 37°C, 5% CO₂ (maintain immature state; no maturation stimuli)
Validate knockdown by qRT-PCR (48h) and flow cytometry (72h)
Verify immature phenotype preserved: CD80low, CD86low, CD83low, MHC-IIlow by flow cytometry
Perform functional assays: T cell priming, cytokine secretion, migration

Cell-Type-Specific Protocols

Monocyte-Derived Dendritic Cells (mo-DCs)

Primary human DCs differentiated from CD14+ monocytes: gold standard for DC research

Monocyte Isolation from PBMCs

Isolate human PBMCs by Ficoll density gradient centrifugation from buffy coats or whole blood. Enrich CD14+ monocytes by positive selection using magnetic bead-based CD14 antibody selection or adherence method (2h adherence in tissue culture flask, wash non-adherent cells). CD14 bead selection yields >95% purity.

Materials: Ficoll-Paque, CD14 magnetic beads, magnetic separation columns

Note: For highest purity: use CD14 positive selection. For cost-effective: use adherence (90-95% purity).

Day -6

DC Differentiation from Monocytes

Culture CD14+ monocytes at 1 × 10⁶ cells/mL in RPMI-1640 + 10% FBS + GM-CSF (50 ng/mL) + IL-4 (25 ng/mL). Cells will differentiate into immature mo-DCs over 5-6 days. At Day 3, add fresh medium with cytokines (50% volume). At Day 6, harvest immature DCs: expect CD14low/−, CD1a+, CD11c+, HLA-DR+, CD80low, CD86low, CD83−.

Materials: Recombinant human GM-CSF, recombinant human IL-4, RPMI-1640 + 10% FBS

Note: Day 6 immature DCs are optimal for ASO treatment. Do NOT add maturation stimuli (LPS, TNF-α, CD40L) unless testing mature DC biology.

Days -6 to 0

AUMsilence Treatment of Immature mo-DCs

At Day 6 (immature DCs), add AUMsilence sdASO directly to culture medium at 10 μM final concentration. For 24-well plate (500 μL medium), add 5 μL of 1 mM AUMsilence stock. Do NOT change medium. Do NOT add maturation stimuli during knockdown period unless experimental design requires it (e.g., testing gene requirement for maturation).

Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

Note: AUMsilence sdASOs enter cells via receptor-mediated endocytosis beginning within 4-6h. Minimal to no maturation observed: immature DCs typically remain CD80low, CD86low with high endocytic capacity.

Day 0

Incubation and Monitoring (Preserve Immature State)

Incubate at 37°C, 5% CO₂ for 48-72h. Monitor cell morphology daily: expect dendritic projections maintained (stellate morphology). Verify no spontaneous maturation: sample small aliquot, stain for CD83 and CD86 by flow cytometry; should remain low. If studying tolerogenic DCs, maintain immature state throughout. If studying maturation requirements, add maturation stimulus (LPS 100 ng/mL, TNF-α 25 ng/mL, or CD40L) at 48h post-ASO.

Materials: Humidified CO₂ incubator

Note: Critical: AUMsilence does NOT induce maturation (verified by no CD80/CD86/CD83 upregulation). This distinguishes it from lipofection.

Days 0-3

Validation of Knockdown and Immature Phenotype

At 48h: extract RNA for qRT-PCR (typically 70-90% mRNA reduction, target-dependent; empirical validation required). At 72h: perform flow cytometry for (1) knockdown validation (surface targets: CD40, PD-L1; intracellular targets: IDO1, IL-12p40 after LPS stimulation), (2) maturation status (CD80, CD86, CD83, HLA-DR; should remain low unless maturation stimulus added), (3) viability (Live/Dead staining; expect >95% viability).

Materials: RNA extraction kit, qPCR reagents, flow antibodies (CD80-FITC, CD86-PE, CD83-APC, HLA-DR-PerCP, viability dye)

Note: For intracellular targets (IDO1, IL-12p40): may need to stimulate DCs (LPS, 6-24h) to induce expression before measuring knockdown.

Days 2-3

Functional Assays Post-Knockdown

At 72h post-ASO, perform functional assays: (1) T cell priming: co-culture DCs with allogeneic naive T cells (DC:T ratio 1:10), measure T cell proliferation (CFSE dilution, 5-7 days) and cytokine production (IFN-γ, IL-2 by ELISA or intracellular flow). (2) Antigen uptake: add fluorescent antigen (DQ-Ovalbumin, pHrodo-labeled proteins), measure uptake by flow cytometry (immature DCs have high uptake). (3) Cytokine secretion: stimulate with LPS (100 ng/mL, 24h), measure IL-12p70, IL-10, IL-6, TNF-α by ELISA. (4) Migration: transwell migration assay toward CCL19 or CCL21 (CCR7 ligands). (5) For DC vaccine applications: load with tumor antigen, assess tumor-specific T cell activation.

Materials: Allogeneic T cells, CFSE, flow antibodies, ELISA kits, DQ-Ovalbumin, transwell plates, CCL19/CCL21

Note: DC function varies by target: IDO1 knockdown increases T cell proliferation. CD40 knockdown reduces T cell priming. TAP1 knockdown abolishes cross-presentation.

Days 3-10

Plasmacytoid Dendritic Cells (pDCs)

Specialized IFN-producing DCs: critical for antiviral immunity and lupus pathology

pDC Isolation from Human Blood

Isolate PBMCs by Ficoll. Enrich pDCs using BDCA-4+ (CD303) positive selection with magnetic bead-based antibody selection. pDCs are rare (0.2-0.5% of PBMCs); expect low yield. Alternatively, use negative selection (deplete T cells, B cells, NK cells, monocytes) to enrich pDCs. Verify purity by flow: pDCs are CD123+ BDCA-2+ BDCA-4+ HLA-DR+ CD11c−.

Materials: BDCA-4 magnetic beads, magnetic separation columns, Ficoll-Paque

Note: pDCs are extremely fragile. Use gentle handling. Culture in RPMI + 10% FBS + IL-3 (10 ng/mL) to maintain viability.

Day -1

AUMsilence Treatment of pDCs

Culture pDCs at 0.5 × 10⁶ cells/mL in RPMI + 10% FBS + IL-3 (10 ng/mL). Add AUMsilence at 5-10 μM (pDCs sensitive; start with 5 μM). Incubate 48-72h. pDCs typically show efficient uptake via receptor-mediated endocytosis (typically 70-85% knockdown).

Materials: AUMsilence sdASO, recombinant human IL-3

Note: pDCs undergo apoptosis without IL-3. Maintain IL-3 throughout culture. Do NOT use lipofection; triggers massive IFN production.

Day 0-3

pDC Activation and IFN Measurement

At 48-72h post-ASO, activate pDCs with TLR7 agonist (R848, imiquimod, 1 μg/mL) or TLR9 agonist (CpG-A ODN2216, 5 μM) for 16-24h. Measure type I IFN production: (1) IFN-α by ELISA (supernatants), (2) IFN-stimulated genes (ISGs) by qRT-PCR: MX1, ISG15, OAS1. Expected results: IRF7 knockdown abolishes IFN-α production. TLR7 or TLR9 knockdown reduces response to respective ligand.

Materials: R848, CpG ODN2216, IFN-α ELISA kit

Note: pDCs produce exceptionally high amounts of IFN-α (100-1000× more than most other cell types depending on stimulation conditions). IRF7 is master regulator; knockdown nearly eliminates IFN-α.

Days 3-4

DC Cell Lines (Human and Mouse)

Human and mouse DC lines for high-throughput screening

Human DC Cell Line Culture and Differentiation

Human DC cell lines can be differentiated from acute myeloid leukemia-derived cells into DC-like cells. Culture in α-MEM + 20% FBS + GM-CSF (100 ng/mL) + TNF-α (2.5 ng/mL) + IL-4 (20 ng/mL) for 5-7 days. Cells differentiate into immature DCs (CD1a+, CD14−, CD80low, CD86low).

Materials: α-MEM, FBS, GM-CSF, TNF-α, IL-4

Note: Human DC cell lines useful for screening applications. More robust than primary DCs.

Days -7 to 0

AUMsilence Treatment of Human DC Cell Lines

Add AUMsilence at 5-10 μM to differentiated human DC cell lines. Incubate 48-72h. Validate knockdown and function similar to primary mo-DCs. For economy option in DC cell lines: consider AUMsaver toASO which requires transfection but is more cost-effective for cell line studies.

Materials: AUMsilence sdASO (or AUMsaver toASO with transfection reagent for economy)

Note: Human DC cell line limitations: Not fully representative of primary DC biology. Validate key findings in primary mo-DCs.

Days 0-3

Mouse DC Cell Line

Immortalized mouse bone marrow-derived DC cell lines can be cultured in α-MEM + 20% FBS + GM-CSF (5 ng/mL). Cells are immature DCs (CD11c+, MHC-IIlow, CD80low). Add AUMsilence (mouse-specific ASO sequence) at 5-10 μM. Useful for rapid screening before moving to primary mouse bone marrow-derived DCs (BMDCs).

Materials: α-MEM, FBS, GM-CSF, mouse-specific AUMsilence

Note: For mouse studies, design ASOs targeting mouse sequences (AUM provides custom mouse ASO design).

Maintain stock culture

Essential Controls for DC Experiments

Untreated Immature DCs: Baseline for maturation markers, cytokine secretion, endocytic capacity

Culture identically but without ASO. Critical for verifying no spontaneous maturation or ASO-induced maturation.

Non-Targeting Control ASO: Control for non-specific ASO effects on DC biology

Use AUM non-targeting control at 10 μM. Verifies phenotypes are target-specific. Critical for DCs given sensitivity to activation.

Maturation Controls: Validate DC maturation capacity

Positive control: LPS (100 ng/mL) + IFN-γ (20 ng/mL) or TNF-α (25 ng/mL) for 24h. Expect CD80high, CD86high, CD83high, MHC-IIhigh, IL-12 production.

Lipofection Comparison (Demonstrates Maturation Artifacts): Optional but powerful demonstration of AUMsilence advantage

Treat immature DCs with lipofection reagent. Measure maturation markers (CD80, CD86, CD83) at 6-24h; expect upregulation. Measure IL-12 by ELISA; expect induction. Compare to AUMsilence: no maturation. Validates why lipofection fails for DC studies.

Optimization Strategies for DC Applications

ASO Concentration

Recommendation: Start with 10 μM for mo-DCs. pDCs may require only 5 μM (more sensitive). DC cell lines (human and mouse): 5-10 μM.

Rationale: DCs are professional phagocytes; efficient ASO uptake. Lower concentrations often sufficient.

Timing for Maturation Studies

Recommendation: Add ASO to immature DCs (Day 0-3). At 48h post-ASO, add maturation stimulus (LPS, TNF-α). Measure maturation at 72-96h total.

Rationale: This tests whether knocked-down gene is required for maturation response. Example: CD40 knockdown prevents LPS-induced maturation.

Timing for Tolerogenic DC Studies

Recommendation: Add ASO at Day 0, maintain immature state (no maturation stimuli) for entire 72h. Verify CD80low, CD86low, IL-12−, IL-10+.

Rationale: Tolerogenic DCs must remain immature. AUMsilence preserves this state (no maturation from ASO itself).

DC-T Cell Co-Culture

Recommendation: Treat DCs with AUMsilence (48-72h), wash, then add to T cells. DC:T ratio 1:10 typical. Measure T cell proliferation (CFSE, 5-7 days).

Rationale: Washing removes excess ASO before T cell addition (though T cells show minimal gymnotic uptake). Prevents confounding T cell effects.

Validation Methods for DC Knockdown

Comprehensive validation ensures authentic DC biology without maturation artifacts.

Flow Cytometry for Maturation Status

Purpose: Critical validation: confirm immature phenotype preserved

Protocol: At 72h post-ASO, harvest DCs, stain for maturation markers: CD80-FITC, CD86-PE, CD83-APC, HLA-DR-PerCP-Cy5.5, viability dye. Gate on live, singlet DCs. Measure median fluorescence intensity (MFI) for each marker. Compare: untreated immature DCs (baseline), non-targeting control ASO (verify no maturation from ASO), experimental ASO (target knockdown), LPS-treated DCs (positive control for maturation).

Expected Results: Immature DCs: CD80low, CD86low, CD83−, HLA-DRintermediate. Mature DCs: CD80high, CD86high, CD83+, HLA-DRhigh. AUMsilence-treated DCs match untreated immature profile.

Tips: CD83 is most specific maturation marker (absent on immature, high on mature). CD86 shows broader range. If any maturation observed with non-targeting control, indicates ASO-induced activation (not observed with AUMsilence).

Cytokine ELISA (IL-12p70, IL-10, IL-6)

Purpose: Measure DC cytokine secretion and verify no inflammatory activation from ASO

Protocol: Collect culture supernatants at 48-72h post-ASO. For induced cytokines: stimulate DCs with LPS (100 ng/mL, 24h) before supernatant collection. Perform ELISA for IL-12p70 (mature DC marker, Th1-inducing), IL-10 (tolerogenic DC marker), IL-6 (pro-inflammatory). Centrifuge supernatants (10,000g, 5 min) to remove debris.

Expected Results: Unstimulated immature DCs: low IL-12p70 (<50 pg/mL), low IL-6, variable IL-10. LPS-matured DCs: high IL-12p70 (500-2000 pg/mL), high IL-6. Tolerogenic DCs: high IL-10, low IL-12.

Tips: If non-targeting control ASO induces IL-12 or IL-6, indicates maturation artifact (not seen with AUMsilence). IL-12p70 is bioactive heterodimer (p35+p40); measure p70, not just p40.

T Cell Priming Assay (Mixed Lymphocyte Reaction)

Purpose: Gold standard functional assay for DC capacity to activate T cells

Protocol: At 72h post-ASO, harvest DCs, wash, co-culture with allogeneic naive T cells at DC:T ratio 1:10 (e.g., 1 × 10⁴ DCs + 1 × 10⁵ T cells in 96-well U-bottom plate). For antigen-specific responses: load DCs with peptide antigen (10 μg/mL, 2h), wash, co-culture with TCR-transgenic T cells (OT-I for OVA, etc.). Label T cells with CFSE (5 μM) before co-culture. Incubate 5-7 days. Measure T cell proliferation by CFSE dilution (flow cytometry) and cytokine production (IFN-γ, IL-2 in supernatants by ELISA or intracellular flow staining).

Expected Results: Mature DCs induce strong T cell proliferation (70-90% divided). Immature DCs induce minimal proliferation (10-30%). Tolerogenic DCs (CD40-knockdown, IL-12-knockdown) induce weak proliferation and Treg induction (Foxp3+ by flow). DC vaccine-engineered DCs (IDO1-knockdown, PD-L1-knockdown) induce enhanced T cell responses.

Tips: Include DC-only and T cell-only controls (no proliferation). Allogeneic MLR measures total DC stimulatory capacity. Antigen-specific assays measure cross-presentation or MHC-II presentation efficiency. For Treg analysis, stain for Foxp3, CD25, measure IL-10 production.

Endocytosis Assay (DQ-Ovalbumin, pHrodo)

Purpose: Measure antigen uptake capacity (immature DCs have high endocytosis)

Protocol: At 72h post-ASO, add fluorogenic antigen: DQ-Ovalbumin (self-quenched, fluoresces upon proteolytic cleavage in endosomes, 10 μg/mL) or pHrodo-conjugated protein (fluoresces in acidic pH, 10 μg/mL). Incubate 30 min to 4h at 37°C. Wash extensively, analyze by flow cytometry (measure fluorescence increase = antigen uptake and processing). Include 4°C control (no endocytosis, only surface binding).

Expected Results: Immature DCs: high endocytosis (strong fluorescence). Mature DCs: reduced endocytosis (10-30% of immature level). AUMsilence-treated immature DCs maintain high uptake.

Tips: Maturation downregulates endocytosis (functional switch from antigen capture to T cell priming). If ASO-treated DCs show reduced uptake, indicates unwanted maturation. DQ-Ovalbumin specific for proteolytic activity; pHrodo measures acidic compartment delivery.

Migration Assay (Transwell to CCL19/CCL21)

Purpose: Measure CCR7-dependent migration (mature DCs migrate to lymph nodes)

Protocol: At 72h post-ASO, harvest DCs (5 × 10⁴ cells in 100 μL serum-free medium), place in transwell insert (5 μm pore for DCs). Add CCL19 or CCL21 (100 ng/mL) to lower chamber (600 μL). Incubate 2-4h at 37°C. Count migrated cells in lower chamber by flow cytometry (using counting beads for accurate quantification) or hemocytometer. Calculate migration index: (cells migrated to chemokine) / (cells migrated to medium control).

Expected Results: Immature DCs: low CCR7, minimal migration (10-20% input). Mature DCs: high CCR7, strong migration (40-70% input). CCR7-knockdown DCs: no migration despite maturation.

Tips: CCR7 upregulation upon maturation enables DC migration from peripheral tissues to draining lymph nodes. This assay validates maturation status and tests CCR7 requirement.

Critical Controls for DC Validation

Untreated Immature DCs

Purpose: Baseline for maturation markers, cytokines, endocytosis, viability

Day 6 mo-DCs without any treatment. Should be CD80low, CD86low, CD83−, high endocytosis, low IL-12.

Non-Targeting Control ASO

Purpose: Control for non-specific ASO effects

Critical for DCs. If non-targeting ASO causes maturation (CD80/CD86 upregulation, IL-12 induction), indicates ASO chemistry issue. AUMsilence non-targeting control causes NO maturation.

LPS or TNF-α Matured DCs

Purpose: Positive control for maturation

LPS (100 ng/mL, 24h) or TNF-α (25 ng/mL, 24h). Should induce CD80high, CD86high, CD83+, HLA-DRhigh, IL-12 production, reduced endocytosis, increased CCR7.

Lipofection-Treated DCs (Optional: Demonstrates Artifacts)

Purpose: Optional but powerfully demonstrates why conventional transfection fails for DC research

Treat immature DCs with any standard lipofection reagent (with or without siRNA). Measure maturation markers at 6-24h post-treatment. Expect CD80/CD86 upregulation, IL-12 induction, and loss of immature phenotype. This control clearly demonstrates the AUMsilence advantage for preserving DC biology.

Frequently Asked Questions

Why does lipofection cause DC maturation?

Cationic lipids trigger DC maturation through TLR2 and TLR4 activation. DCs are sentinel cells equipped with pattern recognition receptors that detect pathogen-associated molecular patterns (PAMPs). Lipoplexes structurally resemble viral or bacterial membranes, activating TLRs and inducing NF-κB signaling within 2-4 hours. This causes upregulation of CD80, CD86, CD83, MHC-II and secretion of pro-inflammatory cytokines (IL-12, IL-6, TNF-α). For studies requiring immature DCs (tolerogenic DC generation, antigen uptake, migration), this maturation artifact destroys experimental validity. Even minimal lipofection causes detectable maturation in 80-90% of treated cells.

How does AUMsilence avoid triggering DC maturation?

AUMsilence sdASOs enter cells via receptor-mediated endocytosis of their phosphorothioate-modified backbones, followed by intracellular trafficking; a small fraction escapes endosomes to reach the cytosol and nucleus where target engagement occurs via RNase H1. Importantly, sdASO designs minimize innate immune activation through sequence filtering to avoid CpG/TLR stimulatory motifs. This mechanism typically does not significantly activate TLRs, induce NF-κB, or trigger cytokine secretion. Validation: measure CD80, CD86, CD83 by flow cytometry at 24-72h post-ASO; typically no significant upregulation compared to untreated immature DCs. Measure IL-12p70, IL-6 in supernatants by ELISA; typically minimal induction. This preservation of immature phenotype is critical for DC research applications.

Can I use AUMsilence in plasmacytoid DCs (pDCs)?

Yes. pDCs are among the most difficult immune cells to transfect: lipofection achieves <5% efficiency with 50-80% cell death, and viral vectors trigger massive type I interferon production (the primary pDC function), creating experimental artifacts. AUMsilence typically achieves 70-85% gene knockdown in human blood-derived pDCs without inducing significant unwanted IFN-α secretion or excessive cell death. Protocol: Isolate pDCs by BDCA-4+ (CD303+) selection, culture in RPMI + 10% FBS + IL-3 (10 ng/mL), add AUMsilence at 5-10 μM, incubate 48-72h. This enables genetic studies of pDC interferon biology (IRF7, TLR7, TLR9, MYD88) that are difficult with other methods.

How do I validate that immature phenotype is preserved?

Multi-parameter validation required: (1) Flow cytometry at 72h: CD80, CD86, CD83, HLA-DR. Immature DCs should remain CD80low, CD86low, CD83−, HLA-DRintermediate. Compare to untreated immature DCs (baseline) and LPS-matured DCs (positive control). (2) Cytokine ELISA: IL-12p70, IL-6 in supernatants should be <50 pg/mL (similar to untreated). (3) Endocytosis assay: DQ-Ovalbumin or pHrodo uptake should remain high (immature DCs have high endocytic activity; maturation downregulates this). (4) Morphology: brightfield microscopy; dendritic projections maintained (maturation or electroporation can cause cell rounding). If all four criteria met, immature phenotype preserved.

Can I knock down multiple genes simultaneously for DC engineering?

Yes. Multi-gene knockdown enables synergistic DC engineering strategies. Examples: (1) Tolerogenic DC: CD40 + CD80 + IL-12B triple knockdown (5 μM each, 15 μM total). Expect maximal T cell hyporesponsiveness and Treg induction. (2) DC vaccine: IDO1 + PD-L1 dual knockdown for combined metabolic and checkpoint targeting. (3) pDC pathways: TLR7 + TLR9 dual knockdown to test pathway redundancy. Use 5 μM per ASO, validate each target knocked down individually (qRT-PCR), test functional synergy in T cell co-culture or cytokine assays. Include single knockdown controls to assess additive vs. synergistic effects.

How long does knockdown last in DCs?

mo-DCs are non-dividing cells; ASO is not diluted by proliferation. mRNA knockdown peaks at 48h and remains stable for 5-7 days. Protein knockdown timing depends on target half-life: short-lived proteins (cytokines: TNF-α, IL-12 upon stimulation, 4-12h half-life) show rapid reduction (24-48h); long-lived surface proteins (CD40, CD80, MHC-II, 48-72h half-life) require 72-96h for maximal knockdown. For DC vaccine manufacturing (clinical applications), single ASO dose at Day 6 (immature DCs) maintains knockdown through antigen loading (Day 7-8) and maturation (Day 8-9) for 3-4 days total. For extended in vitro studies (>7 days), consider re-dosing at Day 5.

Does AUMsilence affect DC migration or T cell priming?

Typically no, unless you target migration or T cell activation genes. AUMsilence treatment (10 μM, 72h) typically does not significantly alter baseline DC function: (1) Migration: CCR7 expression and CCL19/CCL21 responsiveness typically unchanged (verified by transwell migration assay). (2) T cell priming: allogeneic MLR typically shows normal T cell proliferation if targeting non-essential genes. (3) Antigen presentation: MHC-I and MHC-II surface levels typically unchanged. (4) Dendritic morphology: projections typically maintained (unlike some electroporation protocols). However, if targeting functional genes (CCR7, reduced migration; CD40, reduced T cell priming; TAP1, reduced cross-presentation; IL-12B, reduced Th1 priming), expect specific functional defects. This validates target-specific knockdown effects.

Can I use AUMsilence for cross-presentation studies?

Yes: this is a major application. Cross-presentation (presenting extracellular antigens on MHC-I to CD8+ T cells) is unique to DCs, especially cDC1 subset. AUMsilence enables systematic dissection of this pathway: (1) TAP1 or TAP2 knockdown: abolishes cross-presentation (peptide transport into ER blocked) but maintains direct MHC-I presentation of endogenous antigens. (2) SEC22B knockdown: blocks phagosome-to-ER antigen transfer, specific for cross-presentation. (3) ERAP1 knockdown: reduces peptide trimming, alters cross-presented epitope repertoire. Protocol: Knock down target gene (72h), load DCs with extracellular antigen (OVA protein, tumor lysate), co-culture with CD8+ T cells (OT-I TCR transgenic for OVA or tumor-specific), measure T cell activation (IFN-γ, granzyme B, proliferation). TAP1/2-knockdown DCs show no cross-presentation despite normal protein uptake.

What is the difference between cDC1, cDC2, pDC, and mo-DC?

DC subsets have specialized functions: cDC1 (human: CD141+ CLEC9A+, mouse: CD8α+ CD103+): BATF3-dependent, excel at cross-presentation (present extracellular antigens on MHC-I to CD8+ T cells), produce IL-12 for Th1/CTL responses, critical for anti-tumor and antiviral immunity. cDC2 (human: CD1c+, mouse: CD11b+): IRF4-dependent, prime CD4+ T cells via MHC-II, drive Th17 responses, involved in bacterial and fungal immunity. pDC (plasmacytoid DC, CD123+ BDCA-2+ BDCA-4+): produce exceptionally high amounts of type I interferon (IFN-α/β, 100-1000× more than most other cell types depending on stimulation conditions) via TLR7/9, critical for antiviral immunity, implicated in lupus (excessive IFN). mo-DC (monocyte-derived DC): generated in vitro from CD14+ monocytes with GM-CSF + IL-4, not a natural subset but widely used for research and DC vaccine manufacturing. AUMsilence works in all four DC types.

How do I generate tolerogenic DCs for Treg induction?

Tolerogenic DCs induce regulatory T cells (Foxp3+ Tregs) instead of effector T cells, critical for autoimmune disease treatment and transplant tolerance. AUMsilence enables genetic engineering: (1) Differentiate mo-DCs (GM-CSF + IL-4, Day 0-6). (2) Knock down maturation/costimulation genes: CD40 (prevents T cell licensing), IL-12B (prevents Th1), optionally CD80 or CD86. Use 5-10 μM per ASO, 48-72h. (3) Load with antigen (autoantigen for autoimmune diseases, alloantigen for transplant). (4) Do NOT add maturation stimuli; maintain immature state. (5) Co-culture with naive CD4+ T cells (DC:T 1:10, 5-7 days). (6) Validate: Measure Foxp3+ Tregs by flow cytometry, IL-10 production (ELISA), reduced T cell proliferation (CFSE), suppressive function (Treg suppression assay). Published strategy: CD40-deficient DCs induce Tregs (Morelli & Thomson 2007). AUMsilence enables rapid testing without knockout mice or permanent cell line engineering.

Ready to Engineer Dendritic Cells Without Maturation Artifacts?

Discover how AUMsilence enables authentic DC vaccine studies, tolerogenic DC generation, and pDC interferon biology that are impossible with conventional transfection. Our scientists have extensive experience with primary DCs and can help design your experiments.

Order AUMsilence sdASO Request Custom DC Panel Design Consult Our Scientists